171 related articles for article (PubMed ID: 19906261)
21. [CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders].
Gabelle A; Roche S; Lehmann S
Rev Neurol (Paris); 2009 Mar; 165(3):213-22. PubMed ID: 18808768
[TBL] [Abstract][Full Text] [Related]
22. No correlation between time-linked plasma and CSF Abeta levels.
Le Bastard N; Aerts L; Leurs J; Blomme W; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Dec; 55(8):820-5. PubMed ID: 19695299
[TBL] [Abstract][Full Text] [Related]
23. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease.
Munroe WA; Southwick PC; Chang L; Scharre DW; Echols CL; Fu PC; Whaley JM; Wolfert RL
Ann Clin Lab Sci; 1995; 25(3):207-17. PubMed ID: 7605102
[TBL] [Abstract][Full Text] [Related]
24. Imaging and biomarkers for Alzheimer's disease.
Allan CL; Sexton CE; Welchew D; Ebmeier KP
Maturitas; 2010 Feb; 65(2):138-42. PubMed ID: 20060241
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
26. En route to early diagnosis of Alzheimer's disease--are we there yet?
Fradinger EA; Bitan G
Trends Biotechnol; 2005 Nov; 23(11):531-3. PubMed ID: 16165236
[TBL] [Abstract][Full Text] [Related]
27. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.
Song F; Poljak A; Smythe GA; Sachdev P
Brain Res Rev; 2009 Oct; 61(2):69-80. PubMed ID: 19464319
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
29. [Biomarkers for early diagnosis of Alzheimer's disease: current update and future directions].
Malaplate-Armand C; Desbene C; Pillot T; Olivier JL
Rev Neurol (Paris); 2009; 165(6-7):511-20. PubMed ID: 19041993
[TBL] [Abstract][Full Text] [Related]
30. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
[TBL] [Abstract][Full Text] [Related]
31. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
[TBL] [Abstract][Full Text] [Related]
32. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.
Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Machida N; Seiki H; Takase S; Clark CM; Lee VM
Ann Neurol; 1995 Oct; 38(4):649-52. PubMed ID: 7574462
[TBL] [Abstract][Full Text] [Related]
33. Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease.
Lee JW; Namkoong H; Kim HK; Kim S; Hwang DW; Na HR; Ha SA; Kim JR; Kim JW
BMC Neurol; 2007 Jun; 7():14. PubMed ID: 17565664
[TBL] [Abstract][Full Text] [Related]
34. [Neurochemical early and differential diagnostics for Alzheimer's disease].
Wiltfang J; Lewczuk P; Maler M; Bleich S; Smirnov A; Kornhuber J
MMW Fortschr Med; 2004 Sep; 146(38):38-40. PubMed ID: 15532429
[TBL] [Abstract][Full Text] [Related]
35. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers in preclinical Alzheimer's disease.
Chong MS; Lim WS; Sahadevan S
Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
[TBL] [Abstract][Full Text] [Related]
37. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
[TBL] [Abstract][Full Text] [Related]
38. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
Shoji M
Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.
Montine TJ; Markesbery WR; Morrow JD; Roberts LJ
Ann Neurol; 1998 Sep; 44(3):410-3. PubMed ID: 9749613
[TBL] [Abstract][Full Text] [Related]
40. Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease.
Taniguchi M; Okayama Y; Hashimoto Y; Kitaura M; Jimbo D; Wakutani Y; Wada-Isoe K; Nakashima K; Akatsu H; Furukawa K; Arai H; Urakami K
Dement Geriatr Cogn Disord; 2008; 26(2):117-22. PubMed ID: 18654083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
